137 related articles for article (PubMed ID: 27233779)
21. Hypofractionated radiotherapy for organ-confined prostate cancer: is less more?
Arcangeli S; Greco C
Nat Rev Urol; 2016 Jul; 13(7):400-8. PubMed ID: 27296648
[TBL] [Abstract][Full Text] [Related]
22. 11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer.
Franzese C; Lopci E; Di Brina L; D'Agostino GR; Navarria P; Mancosu P; Tomatis S; Chiti A; Scorsetti M
Cancer Invest; 2017 Oct; 35(9):586-593. PubMed ID: 28980836
[TBL] [Abstract][Full Text] [Related]
23. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
Habl G; Straube C; Schiller K; Duma MN; Oechsner M; Kessel KA; Eiber M; Schwaiger M; Kübler H; Gschwend JE; Combs SE
BMC Cancer; 2017 May; 17(1):361. PubMed ID: 28532400
[TBL] [Abstract][Full Text] [Related]
24. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
25. A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy.
Hegde JV; Collins SP; Fuller DB; King CR; Demanes DJ; Wang PC; Kupelian PA; Steinberg ML; Kamrava M
Am J Clin Oncol; 2018 May; 41(5):502-507. PubMed ID: 27322703
[TBL] [Abstract][Full Text] [Related]
26. The Missing Pieces in Reporting of Randomized Controlled Trials of External Beam Radiation Therapy Dose Escalation for Prostate Cancer.
Zaorsky NG; Egleston BL; Horwitz EM; Dicker AP; Nguyen PL; Showalter TN; Den RB
Am J Clin Oncol; 2016 Aug; 39(4):321-6. PubMed ID: 27322694
[TBL] [Abstract][Full Text] [Related]
27. PET Imaging Toward Individualized Management of Urologic and Gynecologic Malignancies.
Sonni I; Iagaru A
PET Clin; 2016 Jul; 11(3):261-72. PubMed ID: 27321030
[TBL] [Abstract][Full Text] [Related]
28. Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy.
Lee JY; Spratt DE; Liss AL; McLaughlin PW
Lancet Oncol; 2016 May; 17(5):e198-208. PubMed ID: 27301047
[TBL] [Abstract][Full Text] [Related]
29. Definition of Insignificant Tumor Volume of Gleason Score 3 + 3 = 6 (Grade Group 1) Prostate Cancer at Radical Prostatectomy-Is it Time to Increase the Threshold?
Kryvenko ON; Epstein JI
J Urol; 2016 Dec; 196(6):1664-1669. PubMed ID: 27291653
[TBL] [Abstract][Full Text] [Related]
30. Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.
Taneja SS; Bennett J; Coleman J; Grubb R; Andriole G; Reiter RE; Marks L; Azzouzi AR; Emberton M
J Urol; 2016 Oct; 196(4):1096-104. PubMed ID: 27291652
[TBL] [Abstract][Full Text] [Related]
31. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries.
Wong MC; Goggins WB; Wang HH; Fung FD; Leung C; Wong SY; Ng CF; Sung JJ
Eur Urol; 2016 Nov; 70(5):862-874. PubMed ID: 27289567
[TBL] [Abstract][Full Text] [Related]
32. Robustness to source displacement in dual air kerma strength planning for focal low-dose-rate brachytherapy of prostate cancer.
Mahdavi SS; Spadinger IT; Chng NT; Morris WJ
Brachytherapy; 2016; 15(5):642-9. PubMed ID: 27263060
[TBL] [Abstract][Full Text] [Related]
33. Factors Affecting Quality of Life at Different Intervals After Treatment of Localized Prostate Cancer: Unique Influence of Treatment Decision Making Satisfaction, Personality and Sexual Functioning.
Victorson DE; Schuette S; Schalet BD; Kundu SD; Helfand BT; Novakovic K; Sufrin N; McGuire M; Brendler C
J Urol; 2016 Nov; 196(5):1422-1428. PubMed ID: 27259651
[TBL] [Abstract][Full Text] [Related]
34. Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.
Lorente D; Omlin A; Zafeiriou Z; Nava-Rodrigues D; Pérez-López R; Pezaro C; Mehra N; Sheridan E; Figueiredo I; Riisnaes R; Miranda S; Crespo M; Flohr P; Mateo J; Altavilla A; Ferraldeschi R; Bianchini D; Attard G; Tunariu N; de Bono J
Clin Genitourin Cancer; 2016 Dec; 14(6):485-493. PubMed ID: 27246360
[TBL] [Abstract][Full Text] [Related]
35. Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction.
Repka MC; Guleria S; Cyr RA; Yung TM; Koneru H; Chen LN; Lei S; Collins BT; Krishnan P; Suy S; Dritschilo A; Lynch J; Collins SP
Front Oncol; 2016; 6():122. PubMed ID: 27242962
[TBL] [Abstract][Full Text] [Related]
36. Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival.
Facchini G; Caffo O; Ortega C; D'Aniello C; Di Napoli M; Cecere SC; Della Pepa C; Crispo A; Maines F; Ruatta F; Iovane G; Pisconti S; Montella M; Berretta M; Pignata S; Cavaliere C
Front Pharmacol; 2016; 7():123. PubMed ID: 27242530
[TBL] [Abstract][Full Text] [Related]
37. The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.
Ma TM; Tosoian JJ; Schaeffer EM; Landis P; Wolf S; Macura KJ; Epstein JI; Mamawala M; Carter HB
Eur Urol; 2017 Feb; 71(2):174-180. PubMed ID: 27236496
[TBL] [Abstract][Full Text] [Related]
38. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.
Sridharan S; Steigler A; Spry NA; Joseph D; Lamb DS; Matthews JH; Atkinson C; Tai KH; Duchesne G; Christie D; Attia J; Holliday EG; Denham JW
Radiother Oncol; 2016 Oct; 121(1):98-102. PubMed ID: 27528117
[TBL] [Abstract][Full Text] [Related]
39. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Dearnaley D; Syndikus I; Mossop H; Khoo V; Birtle A; Bloomfield D; Graham J; Kirkbride P; Logue J; Malik Z; Money-Kyrle J; O'Sullivan JM; Panades M; Parker C; Patterson H; Scrase C; Staffurth J; Stockdale A; Tremlett J; Bidmead M; Mayles H; Naismith O; South C; Gao A; Cruickshank C; Hassan S; Pugh J; Griffin C; Hall E;
Lancet Oncol; 2016 Aug; 17(8):1047-1060. PubMed ID: 27339115
[TBL] [Abstract][Full Text] [Related]
40. Contemporary Gleason grading and novel Grade Groups in clinical practice.
Magi-Galluzzi C; Montironi R; Epstein JI
Curr Opin Urol; 2016 Sep; 26(5):488-92. PubMed ID: 27308734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
